What stood out on Sunday and Monday at the 2023 ASHP Summer Meetings in Baltimore?
Centanafadine is a serotonin-norepinephrine-dopamine triple reuptake inhibitor.
Study results add to the body of evidence demonstrating the efficacy of CGRP inhibitors for migraine treatment and prophylaxis.
A look at how the genetics-based research field can become more fully integrated in all areas of health care going forward.
Although excessive use can lead to fatigue, alerts can help proactively identify and prevent drug interactions.
At least 6 adalimumab biosimilars are set to launch in July 2023.
Q&A: Pharmacist-Led Diabetes Management Transforms Patient Care and Clinical Outcomes
June 28th 2025An ambulatory care pharmacist program in Washington State dramatically improved diabetes management by reducing A1c levels, increasing medication adherence, and providing comprehensive patient education.